333361-15-2

Upstream product

• 333361-13-0 5-bromo-2-methyl-4'-methoxybenzophenone 

Downstream Products

• 333361-21-0 5-bromo-2-methyl-4'-hydroxydiphenylmethane 
• 1369406-00-7 (2S,4R,5S,6R)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(3-(4-methoxybenzyl)-4-methylphenyl)-3,3-difluorotetrahydro-2H-pyran 

Relevant academic research and scientific papers

Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture

Glucopyranosyloxy-substituted benzyl-benzene derivatives of the general formula I where the groups groups R1, R2, R3a, R3b, R4, R5, R6, X and R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture

Glucopyranosyl-substituted benzyl-benzene derivatives of the general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof

The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1, R2 and R3 are defined according to claim 1 and to intermediates of said processes.

Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture

Glucopyranosyloxy-substituted (heteroaryloxy-benzyl)-benzene compounds of the general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

Amino acid complexes of C-aryl glucosides for treatment of diabetes and method

Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formula wherein R1, R2 and R2a are independently hydrogen, OH, OR5, alkyl

C-aryl glucoside SGLT2 inhibitors and method

SGLT2 inhibiting compounds are provided having the formula where R1, R2, and R2aare independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5ior halogen, or two of R1, R2and R2atogether with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R3and R4are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, —OCHF2, —OCF3, halogen, —CN, —CO2R5b, —CO2H, —COR6b, —CH(OH)R6c, —CH(OR5h)R6d, —CONR6R6a, —NHCOR5c, —NHSO2R5d, —NHSO2Aryl, Aryl, —SR5e, —SOR5f, —SO2R5g, —SO2Aryl, or a five, six or seven membered heterocycle, or R3and R4together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5hand R5iare independently lower alkyl; R6, R6a, R6b, R6cand R6dare independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R6and R6atogether with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH2)nwhere n is 0-3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.